For patients who are straightforward candidates, meaning no significant comorbidities, no psychiatric history, no prior GI disease, no eating disorder history, and no drug-drug interaction concerns, Mochi Health's model may be sufficient to deliver the clinical contact points the AACE recommends
Tirzepatide, semaglutide, liraglutide, and, to a lesser extent, naltrexonebupropion provided significant improvement in glycemic parameters and variable rates of type 2 diabetes remission 6 (Table 1)
Your eligibility to take the medication for weight loss will also be assessed
Research Use Only not for human consumption
This means it addresses the desire component of sexual function, not just the physical response